

Be sure. **testo**



The GxP Dictionary

Definitions relating to
GxP and Quality Assurance.

3rd edition

www.testo.com

Note: Some of the information contained in this GxP Dictionary does not apply equally to all countries. Depending on the respective local legislation, other definitions may apply to certain terms and topics. The sections affected are not separately identified.

Foreword

Efficacy, identity and purity are quality attributes, which are required of products from the GMP-regulated environment. The term “Good Manufacturing Practice” sums up the quality assurance requirements from national and international regulations and laws. Other GxP forms have now been developed, whose scope also expands to adjacent sectors such as medical devices and life sciences.

The complex requirements of the “GMP compliance” generate a variety of specific concepts and abbreviations.

This GxP Dictionary explains the majority of terms relating to GxP, qualification, validation and quality assurance. It is intended as a compact reference guide and aid for all those involved in GMP, and does not purport to be complete.

Your Testo team

Contents

- 10 21 CFR 210/211
- 10 21 CFR Part 11
- 10 483
- A**
 - 11 Action limits
 - 11 Active pharmaceutical ingredient (API)
 - 11 ADI
 - 11 AGES
 - 12 Aide mémoire (AiM)
 - 12 Air exchange rate
 - 12 Airlock concept
 - 12 AMBO
 - 12 AMBV
 - 13 AMG
 - 13 AMWHV
 - 13 Annex
 - 14 Annual product review (APR)
 - 14 Approval
 - 14 Audit
 - 14 Audit trail
 - 15 Authorization
 - 15 Autoclave
- B**
 - 16 Barrier systems
 - 16 Batch
 - 16 Batch documentation
 - 16 Batch record review
 - 17 BfArM
 - 17 Bioburden
 - 17 Biological safety cabinet (BSC)
 - 18 BMG
 - 18 BP (British Pharmacopoeia)
 - 18 Bracketing
- 18 British Pharmacopoeia (BP)
- 19 Bubble point test
- 19 Bulk ware
- C**
 - 20 Calibration
 - 20 CAPA
 - 20 Capacity test
 - 20 CEP (certificate of suitability of monographs of the European Pharmacopoeia)
 - 21 CFR
 - 21 CFU (colony-forming unit)
 - 21 cGMP
 - 21 Challenge test
 - 21 Change control
 - 22 CIP
 - 22 Clean corridor principle
 - 22 Cleaning validation
 - 23 Cleanroom
 - 23 Cleanroom classes
 - 24 Cleanroom principle
 - 24 Clean-up period
 - 24 Compliance
 - 25 Computer system/software validation (CSV)
 - 25 Computer validation
 - 25 Concurrent validation
 - 25 Conformity
 - 25 Containment
 - 26 Contamination
 - 26 Continuous validation
 - 26 Control of therapeutic products (cantonal in Switzerland)
 - 27 Corrective action/preventive action

- (CAPA)
- 27 Corrective and preventive actions
- 27 cRABS
- 28 Cross contamination
- 28 CSV
- 28 Culture media
- 28 Culture media filling
- D**
- 29 DAB
- 29 Data review
- 29 Definition of medicinal product
- 30 Design of experiments (DoE)
- 30 Design qualification (DQ)
- 31 Deviation
- 31 Deviation management
- 31 DIN EN ISO 13485
- 32 DIN EN ISO 14644
- 33 Disaster recovery
- 33 Disinfection
- 33 Dispensing
- 33 Distribution
- 34 DMS
- 34 Document management system (DMS)
- 34 DQ
- 34 D-value
- E**
- 35 EC directive
- 35 EC regulation
- 35 EDMF
- 35 eDMS
- 36 EDQM
- 36 EMA guideline
- 36 EMA/EMEA
- 36 Endotoxins
- 37 Entry procedure
- 37 EP
- 37 ETA
- 37 EU GMP Guidelines
- 38 European Pharmacopoeia (Ph. Eur./EP)
- 38 European Pharmacopoeia
- 38 Event tree analysis
- F**
- 39 Factory acceptance test (FAT)
- 39 Fault tree analysis
- 39 FDA
- 40 FDA Guidance for industry – process validation
- 40 Federal Food, Drug and Cosmetic Act
- 40 FFDCA
- 40 Filter fan unit (FFU)
- 41 Fishbone diagram/method
- 41 Flow visualisation
- 42 FMEA (Failure Mode and Effects Analysis)
- 42 FMECA (Failure Mode, Effects and Criticality Analysis)
- 43 Formulation
- 43 FTA
- 43 Functional specification
- G**
- 44 Galenics
- 44 GAMP
- 44 GCP
- 44 GDP
- 44 GEP

- 44 GLP
- 44 GMP
- 45 GMP-compliant plant design
- 45 GSP
- 45 GxP
- H**
 - 46 HACCP
 - 46 Hand disinfection
 - 46 HAZOP
 - 46 Head of production
 - 47 Head of quality control
 - 47 HEPA filters
 - 47 Hygiene design
 - 48 Hygiene zone concept
- I**
 - 49 ICH
 - 49 Information officer
 - 49 In-process controls
 - 50 Installation qualification (IQ)
 - 50 IPC
 - 50 IQ
 - 50 Ishikawa diagram/method
 - 50 ISO 13485
 - 51 ISO 14644
 - 51 Isolator
 - 51 ISPE
- J**
 - 52 Japanese Pharmacopoeia (JP)
 - 52 JP
- L**
 - 53 LAF/LF
 - 53 Laminar (air) flows
 - 53 Life-cycle model
 - 53 Life-cycle approach
- 53 LIMS
- 54 Logbook
- 54 Low-turbulence displacement flow (laminar flow)
- M**
 - 55 Major change
 - 55 Manufacturing authorisation
 - 56 Material flow
 - 56 Matrixing
 - 56 Media fill test
 - 56 Medical device term (according to MPG)
 - 57 Method validation (analytical)
 - 57 Metrological traceability
 - 58 Microbiological monitoring
 - 58 Minor change
 - 58 Monitoring
 - 59 MPG
- N**
 - 60 NOAEL
 - 60 NOEL
- O**
 - 61 Official calibration
 - 61 Operational qualification (OQ)
 - 61 Out of specification (OOS)
 - 61 Out of trend (OOT)
- P**
 - 62 Parenterals
 - 62 Particle monitoring
 - 62 PEI
 - 62 Performance qualification (PQ)
 - 63 Person responsible for technical matters
 - 63 Personnel flow

- 63 Ph. Eur.
 - 64 Pharmaceutical excipient
 - 64 Pharmacology
 - 64 PIC/S
 - 64 Postal audit
 - 65 PPQ
 - 65 PQ
 - 65 PQR
 - 65 Pressure cascade
 - 65 Primary packaging
 - 66 Process
 - 66 Process capability
 - 66 Process capability study
 - 66 Process performance qualification (PPQ)
 - 66 Process validation (PV)
 - 67 Product quality inspection
 - 67 Product quality review (PQR)
 - 67 Product specification
 - 67 Prospective qualification
 - 68 Prospective validation
 - 68 PV (Process validation)
 - 68 Pyrogenicity/pyrogens
- Q**
- 69 QA
 - 69 QbD
 - 69 QP
 - 69 Qualification
 - 69 Qualification master plan
 - 69 Qualification plan
 - 70 Qualification report
 - 70 Qualified person (QP)
 - 71 Qualified person for pharmacovigilance
- 71 Quality assurance (QA)
 - 72 Quality by design (QbD)
 - 72 Quality management manual
 - 72 Quality risk management (QRM)
- R**
- 73 RABS
 - 73 Recovery test
 - 73 Remedies
 - 73 Reproducibility
 - 73 Requalification
 - 74 Requirement specification
 - 74 Reserve sample
 - 74 Responsibility delimitation agreement
 - 75 Restricted access barrier system (RABS)
 - 75 Retrospective qualification
 - 75 Returns
 - 75 Revalidation
 - 76 Risk analysis (RA)
 - 76 Risk assessment
 - 76 Risk communication
 - 76 Risk control
 - 77 Risk management
 - 77 Risk monitoring
 - 77 Risk priority number (RPN)
 - 77 Risk reduction
 - 78 Risk-based qualification systems
 - 78 Robustness
- S**
- 79 Sanitisation
 - 79 Secondary contamination
 - 79 Secondary packaging
 - 79 Self-inspection
 - 79 Shell model

- 80 Sinner's circle
- 80 SIP
- 80 Site acceptance test (SAT)
- 81 Site master file (SMF)
- 81 SOP (standard operating procedure)
- 81 Specification
- 81 Sterile filtration
- 82 Sterility
- 82 Sterilization
- 82 Stress-test
- 82 Supplier audit
- 83 Swissmedic
- 84 TAMC (Total Aerobic Microbial Count)
- 84 Test plan
- 84 Therapeutic products act (HMG)
- 84 Third-party audits
- 84 TOC measurement
- 85 Traceability
- 85 Traceability matrix
- 85 Track & trace
- 86 Turbulent flows
- 86 TYMC (Total Yeasts/Moulds Count)
- 87 URS (user requirement specification)
- 87 USP
- 88 V model
- 89 VAC system
- 89 Validation
- 89 Validation master plan (VMP)
- 90 Validation matrix
- 90 Validation plan
- 90 Validation report
- 90 VDI 2083
- 92 Warning letter
- 92 Warning limit
- 92 WHO
- 93 WIP
- 93 Work instruction
- 93 Worst-case scenario
- 94 ZLG

Terms and Definitions

21 CFR 210/211

CFR: Code of Federal Regulations – Federal Regulations of the USA

Title 21: Food and Drugs – contains the regulatory provisions for the food and drugs sector.

Part 210: current Good Manufacturing Practice (see “Change Control” on page 21) in manufacturing, processing, packing, or holding of drugs; general

Part 211: current Good Manufacturing Practice (see “Change Control” on page 21) for finished pharmaceuticals

The 21 CFR 210/211 contains very detailed GMP guidelines for the USA. Part 210 refers to the manufacturing and packaging process of drugs and food, while Part 211 primarily includes the rules for finished pharmaceuticals.

21 CFR Part 11

CFR: Code of Federal Regulations – Federal Regulations of the USA

Title 21: Food and Drugs – contains the regulatory provisions for the food and drugs sector.

Part 11: Electronic Records; Electronic Signatures. FDA guidance on electronic records and electronic signatures

21 CFR Part 11: The criteria established determine under what circumstances electronic records and signatures are considered equally trustworthy, reliable and equivalent to paper records and handwritten signatures.

483

The problem report is referred to as 483, and it is issued by FDA inspectors (see “FDA” on page 39) and documents the complaints that arise during an inspection. The name

is derived from Form No. 483, which is used to prepare the summary report. A 483 is normally published, but without naming the company or product names concerned. Depending on the relevance of the documented defects, a Warning Letter is created on the basis of the 483. (see “Warning Letter” on page 92).

Action limits

A limit value stipulated by laws, directives or internal company provisions. If this value is exceeded, then corrective actions must be initiated without delay, accompanied by analysis of the failure and removal of the cause.

Active pharmaceutical ingredient (API)

The medically (pharmacologically) active ingredient in a drug.

ADI

Acceptable daily intake: The ADI specifies the amount of a certain substance, e.g. of an active pharmaceutical ingredient, that does not present any health risk, on the assumption that a person is exposed to it on a daily basis over a lifetime.

AGES

= Agency for Health and Food Safety: AGES is owned by the Republic of Austria. Its tasks arise from the Health and Food Safety Act and European food safety policy.



Aide mémoire (AiM)

Catalogue of guidelines, questions and recommendations; issued by the ZLG (see “ZLG” on page 94) as a guideline for the inspection of companies in the pharmaceutical and medical device industry in Germany. Some AiMs are publicly accessible via the ZLG homepage (www.zlg.de).

Air exchange rate

The air exchange rate is the air volume flow in relation to the room volume, i.e. the air exchange rate is an indication of how often the total air volume in a room with a turbulent flow profile is exchanged per hour and is an important criterion for assessing the performance of a cleanroom.

Airlock concept

Airlock concepts consist of several rooms, arranged one behind the other, which allow the transition of persons and material from a cleanroom area to a cleanroom area with a higher or lower level of purity, without contaminating one of the areas.

AMBO

= Medicinal Products Operating Regulations (Austria): Ordinance of the Federal Ministries of Health, Family and Youth concerning companies that manufacture, control or place medicinal products on the market.

AMBV

= Medicinal Products Authorisation Ordinance: Ordinance on Licences in the Medicinal Products Sector in Switzerland.

AMG

= Medicinal Products Act (Germany). Contains 147 paragraphs and 18 sections, e.g. on the manufacture and authorisation of medicinal products and the protection of humans during clinical trials. “§ 1 Purpose of the law: The purpose of this Act is to ensure the safety of the trade in medicinal products, in particular the quality, efficacy and safety of medicinal products in accordance with the following provisions, in the interests of the proper supply of medicinal products to humans and animals.”

AMWHV

= Ordinance on the Manufacture of Medicinal Products and Active Substances:

Ordinance on the application of good manufacturing practice in the manufacture of medicinal products and active substances and on the application of good professional practice in the manufacture of products of human origin. The AMWHV implements the European GMP requirements for Germany. All GMP-regulated companies must be organised according to these specifications.

Annex

Annexes are various appendices to the EU GMP Guidelines. Currently there's Annex 1 to Annex 19, there is no longer an Annex 18. Annex 18 was published in 2005 as EU GMP Guidelines Part II.

Annual product review (APR)

A retrospective review of the history of a drug, required by the FDA for products manufactured in or imported into the USA, undertaken on an annual basis.

Approval

Approval may only be granted by a qualified person in accordance with Section 14 AMG and is the last step before a batch is placed on the market. It is only issued on the condition that the manufacturing and testing process has been carried out in accordance with the regulations and specifications and that this has also been correctly documented.

Audit

Inspection or survey of a site (e.g. a company, a production site) for the purpose of verifying compliance with the requirements it is supposed to fulfil (here: compliance with the GMP regulations and their specifications). An audit can be carried out by various bodies (e.g. representatives of contracting authorities or representatives of authorities other than the competent supervisory authority such as the FDA) and, in terms of how it is defined, is separate from an inspection, which may be carried out exclusively by the competent supervisory authority, i.e. inspectors of the state authorities.

Audit trail

This is used to ensure the complete traceability of all activities, actions and system states by recording “traces”, which indicate when, by whom and/or what, a process was

influenced. It usually consists of records of computer and software systems and is required by 21 CFR Part 11 as well as Annex 11 (EU GMP).

Authorization

Authorization refers to the marketing authorization for a medicinal product. In this regard, the product must always conform to the GMP. In Germany, authorisation is granted by the BfArM or PEI; in the USA by the FDA.

Autoclave

In the GMP field, an autoclave is a pressure chamber in which a wide variety of products can be autoclaved, i.e. sterilised (e.g. cleanroom clothing), for a certain period of time under the influence of steam at defined pressure and temperature values.

Barrier systems

A barrier system is used, for example in aseptic filling processes, to physically separate personnel and product from each other in order to ensure both employee protection from highly active substances and the prevention of microbiological contamination of the product. Examples of such barrier systems are workbenches and isolators as well as RABS systems see “Restricted Access Barrier System (RABS)” on page 75.

Batch

A homogeneous and defined quantity of starting material, medicinal products or packaging material produced in a single operation or in a series of operations.

Batch documentation

The batch documentation includes instructions and protocols on manufacturing and packaging procedures, as well as the test report. This enables the entire history of a batch to be traced without any gaps. The Batch Documentation serves as a basis for the batch release and is particularly important when, at a later stage, quality defects are identified which were not detectable at the time of release.

Batch record review

Batch record review is a system that collates all the information about the batch certification. For example, these include batch production and test reports, as well as all records of deviations and OOS reports (see “Out of specification (OOS)” on page 61). This information is



used by the QP (Qualified Person) as the basis for making decisions regarding the release of a batch (batch release).

BfArM

= Federal Institute for Drugs and Medical Devices:
Federal authority of the BMG;

Responsibilities of the BfArM:

- Authorisation of finished medicinal products on the basis of the Medicinal Products Act
 - Collection & evaluation of reports of adverse reactions that only become known after authorisation
 - Registration of reports on incidents involving medical devices: centralised recording, evaluation and assessment of risks arising from the use of the devices and coordination of the measures to be taken
 - Bundesopiumstelle (part of the BfArM): Authorisation to legally place narcotics and corresponding precursors on the market
-



Bundesinstitut
für Arzneimittel
und Medizinprodukte

Bioburden

= microbial load: Total number of viable microorganisms on or in medicinal products before sterilisation.

Biological safety cabinet (BSC)

This is often used in microbiological or analytical laboratories and is a “room within a room” concept to protect employees and the environment, along with the product, when carrying out critical processes.

Class I: BSC with work access opening; prevents airborne suspended contamination via inward flow of air and filtration of the exhaust air.



*BSC Class III: Isolator
(Image: Franz Ziel GmbH)*



Bundesministerium
für Gesundheit

Class II: BSC with work access opening; reduces the risk of cross-/product contamination via filtered circulating air and filtration of the exhaust air.

Class III: BSC (e.g. isolator) with completely closed-off working area (physical barrier). Intervention in the working area is possible, e.g. using gloves.

BMG

= Federal Ministry of Health: drafts laws, ordinances and administrative regulations.

The most relevant task area for the GMP sector:

The design of the framework regulations for the manufacture, clinical testing, authorisation, distribution channels and monitoring of medicinal products and medical devices.

BP (British Pharmacopoeia)

see British Pharmacopoeia

Bracketing

Concept of a validation in which the batches are only tested for extremes of certain defined and justified design factors. In cleaning validation, bracketing is to be understood as a product-related process. Lead substances are defined here. Similar products/processes therefore do not have to be validated individually, but a representative and risk-based spectrum is sufficient.

British Pharmacopoeia (BP)

The British Pharmacopoeia is the collection of official standards that apply to medical devices and pharmaceutical

substances within the UK. These regulations are issued and updated annually by the British Pharmacopoeia Commission Secretariat of the Medicines and Healthcare Products Regulatory Agency.

Bubble point test

The bubble point test can be used to check a filter for possible damage or defects by using the bubble point to draw conclusions about the maximum pore size. For this purpose, the filter is immersed in a wetting liquid and pressurised with gas pressure, which is slowly increased. The minimum pressure that leads to the first bubble escaping from the filter indicates the bubble point. The lower this pressure, the larger the maximum pore size of the filter.

Bulk ware

= Any product which has passed through all processing stages except for final packaging.

Calibration

Calibration is the comparison of a reading or a material measure with the correct value under stipulated conditions, documentation of the deviation, calculation of the measurement uncertainty and creation of the certificate or calibration certificate. One of the most important criteria for professional calibration is complete metrological traceability to national and international standards.

CAPA

see “Corrective Action/Preventive Action (CAPA)” on page 27

Capacity test

The Capacity Test is a long-term stress test to show whether an (IT) system remains functional even under full load over the long term. Possible capacity limits are therefore visible. For instance, a document management system should launch the correct workflow following a document becoming valid, even if, for example, hundreds of documents become valid at the same time.

CEP (Certificate of Suitability of Monographs of the European Pharmacopoeia)


The certificate confirming that a drug has been produced in line with the monographs of the European Pharmacopoeia.

CFR

= Code of Federal Regulations: Federal regulations of the USA.
Example: 21 CFR 210 and 211

CFU (colony-forming unit)

Used for the qualification of micro-organisms/germs in microbiology. In a wipe test, for example, nutrient medium is applied to a surface for a certain time (e.g. 10 seconds). Following incubation of the nutrient medium, the micro-organism multiplies and becomes visible as a colony (= CFU).



CFU on agar plate

cGMP

= current Good Manufacturing Practice: Since the US GMP guidelines are continuously being revised, the correct name is cGMP. Whereas in Europe the guidelines are only updated as required, so the c (current) is not necessary. So its title here is just GMP.

Challenge test

Challenge test refers to a qualification or validation test under worst-case conditions. This method is often supplemented by the deliberate inducement of faults in order to prove that these can be detected and remedied or prevented by the actions taken.

Change control

Formal system for maintaining the defined status, e.g. the validation status. A systematic, risk-based assessment is carried out, to find out what measures are required due to an intended or actual change, in order to maintain GMP



conformity and, for example, the specification. These measures are assessed by qualified representatives of the relevant department.

CIP

= Cleaning In Place: Automated system cleaning within a closed system, which is implemented using so-called spray balls, for example.

Clean corridor principle

The clean corridor is a protection concept for preventing cross-contamination. Here, a spatial arrangement is provided, in which the corridor, which leads to various processing areas, is the space with the highest pressure. Thus, the overflow is directed towards the production rooms, which prevents a product from being discharged into another area.

Cleaning validation

The cleaning validation is documented proof that a cleaning procedure can be used to achieve a plant status that is suitable for the production of medicinal products. The effectiveness and reproducibility of the entire cleaning procedure is verified to this end. The four decisive parameters that influence the success of the cleaning are portrayed in Sinner's circle: Chemistry, mechanics, temperature and time (cf. "Sinner's circle" on page 80). Another prerequisite for successful cleaning is GMP-compliant plant design.

Cleanroom

A cleanroom is a room designed so as not to exceed a defined particulate and microbiological contamination. In accordance with the purity specifications that this type of room fulfils on a permanent basis, a purity classification is attributed to it. Moreover, a cleanroom is equipped with airlocks and access protection.



Cleanroom at Testo Industrial Services

Cleanroom classes

In DIN EN ISO 14644-1, the different cleanroom classes (ISO 1-9) are classified according to the maximum permissible particle concentration (in particles per cubic metre of air). ISO class 1 is the cleanroom class with the lowest permissible particle concentration. In the EU GMP guidelines, the letters A to D are assigned to the cleanroom classes, and a distinction is also made between production and idle state.

Classification limits in Annex 1

EU Guidelines to Good Manufacturing Practice, Annex 1, 08/2022

Room class	Maximum permissible number of particles per m ³ , equal to or greater than the tabulated size			
	Resting state		Production	
	≥ 0.5 µm	≥ 5.0 µm	≥ 0.5 µm	≥ 5.0 µm
A	3,520 ISO 5	Not specified	3,520 ISO 5	Not specified
B	3,520 ISO 5	Not specified	352,000 ISO 7	2,930
C	352,000 ISO 7	2,930	3,520,000 ISO 8	29,300
D	3,520,000 ISO 8	29,300	Not defined	



Particle limit values (permanent monitoring)

EU Guidelines to Good Manufacturing Practice, Annex 1, 08/2022

Room class	Maximum permissible number of particles per m ³ , equal to or greater than the tabulated size			
	Resting state		Production	
	≥ 0.5 µm	≥ 5.0 µm	≥ 0.5 µm	≥ 5.0 µm
A	3,520 ISO 5	29 ISO M (29;≥ 5 µm; LSAPC)	3,520 ISO 5	29 ISO M (29;≥ 5 µm; LSAPC)
B	3,520 ISO 5	29 ISO M (29;≥ 5 µm; LSAPC)	352,000 ISO 7	2,930 ISO 7
C	352,000 ISO 7	2,930 ISO 7	3,520,000 ISO 8	29,300 ISO 8
D	3,520,000 ISO 8	29,300 ISO 8	Not defined	

Cleanroom principle

The Cleanroom Principle is a protection concept that works via a shell model with overpressure to adjacent areas of low air purity. The overflow therefore moves away from the cleanroom, preventing any impure air from getting into the cleanroom (see “Pressure cascade” on page 65).

Clean-up period

Measurement of the time required for a cleanroom with a turbulent flow profile to reach the particle concentration specification for the “at rest” operating state after the end of a process. This is used to determine the duration for the transition of the operating states from “in operation” to “at rest”.

Compliance

Conformity of conditions with standards and specifications. GMP compliance is therefore compliance with the GMP Regulations, i.e. the relevant laws, directives and guidelines (e.g. EU GMP Guidelines).



Computer system/software validation (CSV)

see “Computer Validation” on page 25

Computer validation

= Validation of computerized systems: According to the EU GMP Guidelines, a computer consists of “a combination of hardware components and associated software, designed and put together in order to carry out a specific function or group of functions”. During computer validation, the suitability of this hardware/software conception for achieving the required functions is checked and the results documented.

Concurrent validation

The validation takes place while the products intended for subsequent sale are being manufactured. Commencement of routine production prior to the completion of the validation process must be justified, documented and approved by authorized personnel. The validation batch is only released for trading following successful validation.

Conformity

see “Compliance” on page 24

Containment

Containment of a biological agent or other substance within a defined space.

Primary containment: Prevents leakage into the immediate work environment (e.g. via closed containers).



Secondary containment: Prevents leakage to the outside or into other work environments (e.g. via rooms with special ventilation systems/airlocks).

Contamination

The unwanted introduction of foreign substances or impurities, chemical or microbiological, into or onto a starting material or intermediate or finished product during manufacture, sampling, packaging, storage or transport.

Continuous validation

Validation is no longer seen as a temporary, one-off activity, but as a permanent verification that accompanies the process over the entire period, from the design phase through to the market withdrawal of the product. The new process validation approach therefore consistently follows the life-cycle model. In a broader sense, therefore, each batch produced is a validation batch.

Control of therapeutic products (cantonal in Switzerland)

The current tasks of the Swiss supervisory authority are set out in the following laws:

- Federal Act on Medicinal Products and Medical Devices
- Federal Act on Narcotics and Psychotropic Substances
- Federal Act on the University Medical Professions
- Health Act (Canton Zurich)

These decrees define the responsibilities of the federal and cantonal supervisory authorities involved in the areas of market authorisation and market surveillance of therapeutic products. The cantons have delegated certain

control tasks to their regional specialised offices. The Cantonal Therapeutic Products Inspectorate is one of these competence centres. The former Intercantonal Agency for the Control of Therapeutic Products (ICS) was transferred to the Swiss Agency for Therapeutic Products Swissmedic on 1 January 2002 (see “Swissmedic” on page 83).

Corrective action/preventive action (CAPA)

Systematic approach that includes both corrective and preventive actions.

Corrective action: Action taken to eliminate the cause of a fault in an identified, undesirable situation and to have a strong chance of preventing recurrence in other areas too or in another procedure.

Preventive action: Action taken to actively prevent the cause of a potential failure. This is often done with the aid of risk analyses.

Corrective and preventive actions

see “Corrective Action/Preventive Action (CAPA)” on page 27

cRABS

= closed RABS (Restricted Access Barrier System): A closed RABS is completely airtight from the room in which the person operating it is located, whereas the design of a standard RABS may well include openings, for example for the air flow to escape (these must of course be designed in such a way that it is not possible to “reach in”) (see “RABS” on page 75).



Cross contamination

Contamination of a starting material or product by undesired mixing with another material during the manufacturing process.

CSV

= Computer system validation/computer and software validation (see “Concurrent validation” on page 25)



Agar plates in various versions

Culture media

Used in microbiology to cultivate microorganisms. Culture media are available in liquid and solid form (agar) and contain the most important nutrients for microorganisms. Selective culture media are designed for specific microorganisms due to their ingredients. This can reduce or prevent the growth of undesirable germ types.

Culture media filling

see “Media fill test” on page 56

DAB

= German Pharmacopoeia: contains supplementary regulations to the EP (European Pharmacopoeia) on procedures and active substances that are not common in all European countries. The DAB can be obtained from Deutscher Apotheker Verlag and consists of the three pharmacopoeias European Pharmacopoeia, German Pharmacopoeia and Homeopathic Pharmacopoeia (HAB).

Data review

A data review can replace a practical revalidation, assuming that no critical changes have been made to the process since the validation. In that case, evaluating the process and product data for the last period is sufficient; there is no need to check the validated status for specific batches.

Definition of medicinal product

– according to **AMG, § 2:**

(1) Medicinal products are substances or preparations of substances which 1. are intended for use in or on the human or animal body and are intended as agents with properties for the cure or alleviation or prevention of human or animal diseases or pathological conditions or 2. may be used in or on the human or animal body or administered to a human or animal either a) to restore, correct or influence physiological functions by a pharmacological, immunological or metabolic action or b) to establish a medical diagnosis.

– according to HMG; **Art. 4 §. 1a:**

Products of chemical or biological origin intended or advertised for medical use on the human or animal organism, in particular for the detection, prevention or



treatment of diseases, injuries and disabilities; medicinal products also include blood and blood products.

Design of experiments (DoE)

= Statistical design of experiments; method for determining the relationship between influencing factors and the results of a process. By changing the factors that can be influenced and measuring the resulting outcomes, the correlations are to be described using coefficients in a model. The relationship between control and disturbance variables in the process and the resulting product and process properties is determined.

Design qualification (DQ)

= Design Qualification: Documented evidence that the design intended for fixtures, fittings and equipment is suitable for the intended use. The DQ, which takes place before the equipment is purchased, comprises the documentation of the planning phase, including the decision-making process for the purchase of a system. The requirements for the planned installation should be defined and specified. The elements of the DQ are usually:

- The design qualification plan,
- The user requirement specification,
- The requirement specification (= the client's requirements with regard to the scope of supply and services)
- The functional specification (= the contractor's design for implementing the plant or the project) and
- The design qualification report.

The DQ is the documentation of the comparison between the requirement specification and the functional

specification, as well as the underlying laws, regulations and standards.

Deviation

In general, a deviation may be described as a result or a situation within a process which does not comply with the plan or expectations or even a specific related provision. Examples of these are deviations involved in quality control, monitoring or product specifications.

Deviation management

Deviation management is the standardized, controlled handling of a deviation. This includes the detection, analysis or monitoring and also remedying of a deviation. Both the causes of a deviation and the related implications must be recorded and classified. This procedure ensures that failures and their consequences are corrected efficiently, and enables early detection of critical situations as well as the implementation of appropriate countermeasures in future.

DIN EN ISO 13485

DIN EN ISO: Standard of the German Institute for Standardisation based on an international standard developed by ISO and/or CEN.

ISO 13485 defines the content and structure of the quality management system for medical devices, which can be applied to the design and development, production, installation and also maintenance of medical devices. It is derived from ISO 9001, and adds to this the specific requirements for the field of medical devices.

DIN EN ISO 14644

ISO 14644 deals with cleanrooms and contamination control. The products and processes that benefit from controlled airborne contamination include those used in the aerospace, microelectronics, pharmaceutical and food industries as well as in medical technology and healthcare. In addition to the particle purity of the air, lots of additional aspects need to be taken into consideration in the planning, specification, operation and monitoring of cleanrooms and other related areas. The standard is therefore subdivided into different parts (as of: 10/2023):

- 14644-1: Classification of air cleanliness by particle concentration
- 14644-2: Monitoring to provide evidence of cleanroom performance related to air cleanliness by particle concentration
- 14644-3: Test methods
- 14644-4: Design, construction and start-up
- 14644-5: Operations
- 14644-6: Terms and definitions (2014-04-23 withdrawn by ISO)
- 14644-7: Separative devices (clean-air hoods, glove boxes, isolators and mini-environments)
- 14644-8: Classification of airborne molecular contamination
- 14644-9: Assessment of surface cleanliness for particle concentration
- 14644-10: Assessment of surface cleanliness for chemical contamination
- 14644-12: Specifications for monitoring air cleanliness by nanoscale particle concentration
- 14644-13: Cleaning of surfaces to achieve defined levels of cleanliness in terms of particle and chemical classifications

- 14644-14: Assessment of suitability for use of equipment by airborne particle concentration
 - 14644-15: Assessment of suitability for use of equipment and materials by airborne chemical concentration
 - 14644-16: Energy efficiency in cleanrooms and separative devices
 - 14644-17: Particle deposition rate application
 - 14644-18: Assessment of suitability of consumables (under development)
-

Disaster recovery

= Recovery following an IT blackout; This includes the recovery of important data as well as the repair or replacement of destroyed hardware components.

Disinfection

Disinfection involves the targeted reduction of certain undesirable germ spectra with the aim of preventing them from spreading further.

Dispensing

The transfer or provision of a medicinal or therapeutic product for use by the acquirer or for use on third parties or on animals, whether in return for payment or free of charge (TPA; Art. 4f).

Distribution

The transfer or provision of a therapeutic product or medicinal product in return for payment or free of charge, with the exception of dispensing (TPA; Art. 4e).



DMS

see “Document Management System (DMS)” on page 34

Document management system (DMS)

This is a software application or system used to capture, process, store, manage and track electronic documents and files such as reports, invoices, contracts and e-mails.

DQ

see “Design qualification (DQ)” on page 30

D-value

The D value specifies a dose or time period by which a certain germ (test microorganism) is reduced by one log level or 90 % under defined conditions due to death processes (inactivation). The D value is an important parameter in sterilisation processes (e.g. thermal sterilisation).

EC directive

= Legislation of the European Community: Member States have a certain amount of flexibility when it comes to their transposition into national law (transposition into law or regulation).

EC regulation

= Legislative act of the European Community: this has general application, is binding in its entirety and is valid in all Member States – i.e. it does not have to be transposed into national law, which also means that no modifications are possible.

EDMF

= European Drug Master File: A Drug Master File documents the pharmaceutical production & quality assurance of drugs. This document is used for submission to the competent authority for medicinal products for the authorization of a drug. An EDMF is usually used when the manufacturer of the drug and the manufacturer of the finished dosage form are not identical. The pharmaceutical manufacturer can therefore safeguard its product secret by describing the synthetic routes and process development of the preparation only in the confidential section of the Drug Master File. This section is accessible to the competent authority, but not to the pharmaceutical manufacturer.

eDMS

see “Document management system (DMS)” on page 34



EDQM

= European Directorate for the Quality of Medicines and HealthCare: The EDQM is responsible for the development and publication of the European Pharmacopoeia, coordinates the regular testing of medicinal product samples by the relevant testing centres of the member states and releases standard substances for quality testing. The EDQM's contact point for sampling from the German market is the ZLG.

EMA guideline

= Guideline issued by the European Medicines Agency, e.g. on human and veterinary drugs, health protection and GDP (see "GMP" on page 44).



EMA/EMEA

= European Medicines Agency: The EMA is a decentralized EU agency based in London. Since 1995, it has been responsible for the scientific evaluation of medicinal products developed by pharmaceutical companies for use within the European Union. The EMA plays a central role in drug registration within the EU and the EEA States, since the European Commission issues authorizations on the basis of its assessments.

Endotoxins

Pyrogens that occur in the form of lipopolysaccharides in the bacterial cell wall of gram-negative bacteria. Endotoxins can trigger reactions ranging from fever to death in patients through parenteral administration. Endotoxins can be detected using the rabbit pyrogen test or the so-called LAL test.

Entry procedure

The entry procedure consists of precisely defined donning and doffing instructions for the process or product-specific workwear in a cleanroom, e.g. to avoid contamination of the outside of cleanroom clothing when dressing. Generally, changing is done from top to bottom. When entering a higher classified cleanroom area from a cleanroom, an additional changing procedure is required. In addition, hand hygiene measures are necessary for the introduction of employees.

EP

= European Pharmacopoeia: Published by the European Directorate for the Quality of Medicines & Health Care (EDQM); this contains the official standards and methods applicable to medical devices and pharmaceutical substances within the EU.

ETA

see “Event Tree Analysis” on page 38

EU GMP Guidelines

= Good Manufacturing Practice guidelines: The first version of these guidelines, in which the European directives are implemented in detail, was published in 1989. It now consists of 4 parts in addition to Annexes 1-19.

Part I: GMP principles for the manufacture of medicinal products.

Part II: Good Manufacturing Practice for active substances.

Part III: GMP-related documents (including Quality Risk Management).


Part IV: GMP requirements for advanced therapy medicinal products.

European Pharmacopoeia (Ph. Eur./EP)

see “EP” on page 37

Event tree analysis

The “event tree analysis” is a method for determining the possible consequences that are triggered by a failure. From an initial failure, a tree diagram is developed via various paths, which represent the possible reactions of the individual system components, culminating in all possible failure consequences and implications.




Factory acceptance test (FAT)

Acceptance/control of ordered devices and plants on site at the supplier's premises. The site acceptance test (see "Site acceptance test (SAT)" on page 80) is usually carried out after delivery and installation.


Fault tree analysis

In fault tree analysis, the tree diagram, in contrast to the event analysis (cf. "Event tree analysis" on page 38), progresses from the failure to the cause. In other words, this explores the most likely cause or combination of causes of a fault.



FDA

= U. S. Food and Drug Administration; the FDA is the highest health authority in the USA and is responsible for drug licensing. In order to ensure compliance with the standards also with regard to the many medicinal products imported into the USA, the FDA operates internationally and carries out audits among exporting producers outside the USA.



FDA Guidance for industry – process validation

Contains non-binding recommendations for implementing the process validation, which are based on the current perspective of the US FDA agency. It is important to note that it is possible to also focus on other guidelines, provided that compliance with all GMP regulations is ensured.

Federal Food, Drug and Cosmetic Act

= U.S. Federal legislation on food, drug and cosmetics: The FFCA is the legal basis for all actions and the existence of the FDA. Compliance with this law is ensured through inspections of factories and products, sample analyses and consumer education.

FFCA

See “Federal Food, Drug and Cosmetic Act” on page 40




*Laminar flow unit with FFU
(Image: Franz Ziel GmbH)*

Filter fan unit (FFU)

Filter Fan Unit refers to a combined component consisting of a fan and filter, which draws in air on one side and discharges it on the other side through the filter into a self-contained (clean) room. In addition to this room-in-room solution, an FFU can also be supplied with air via a supply network. While a local recirculation FFU can only increase the air exchange rate to remove particulate loads and is used for local protection concepts, a centrally supplied FFU can be used to introduce additional fresh air into the cleanroom and supply the required air volume to maintain the pressure cascade.


Fishbone diagram/method

The fishbone method (also Ishikawa diagram) is a graphical method for displaying failures/causes and resultant effects (consequence of failures). Its name is derived from the visual similarity to a fishbone. The method is often also named after the person who developed it, Kaoru Ishikawa. Thanks to the form of presentation, this method imparts a good understanding of the process, which leads to a clear objective.



Flow visualisation

Flow visualisation is used in the context of cleanroom qualification to visualise the air flows to verify a TAV flow or overflows in pressure cascades. For this purpose, fog is introduced into the air flow using a so-called flow marker or fog generator. The flow visualisation is carried out at all critical overflow points, e.g. door gaps, pass-throughs



and airlocks. Documentation is carried out with the aid of photographs and/or video recordings.

FMEA (Failure Mode and Effects Analysis)

= Failure mode and effects analysis: FMEA is a risk analysis method, which is used to analyze individual failures as well as failure effects and causes. It is widely used in industries where there are high standards with respect to product and process reliability. The FMEA is currently the most frequently used method for systematic risk analysis in the pharmaceutical industry and can also depict extremely complex considerations. Depending on the type of FMEA, the interaction of components in a complex system (system FMEA), the design of products or components (design FMEA) or the steps of a production or service process (process FMEA) are considered. In the FMEA, a Risk Priority Number (see “Risk priority number (RPN)” on page 77) is determined for each individual sub-step in a process. If this exceeds a pre-defined limit value, risk-reduction measures need to be taken.

FMECA (Failure Mode, Effects and Criticality Analysis)

= Failure meaning analysis: FMECA is an extension of the FMEA to include the “criticality” factor or the “magnitude of the consequences of a failure” (see “FMEA (Failure Mode and Effects Analysis)” on page 42).

Formulation


The formulation of a medicinal product includes its preparation with the appropriate ingredients as well as its form (dosage form). Once the formulation process of a product is completed, it is referred to as bulk ware.

FTA

see "Fault tree analysis" on page 39

Functional Specification

The functional specification contains the contractor's comments on the implementation and processing of a project (e.g. construction of a facility). It is the supplier's detailed description for the implementation strategy of the requirement specification, and should therefore contain all the obligatory requirements referred to therein. Often no separate Functional Specification is created. Instead it is replaced by the contractor's corresponding offer, provided that this has been adequately detailed.



Galenics

The science of drug production. This includes the moulding and technological testing of the drugs.

GAMP

= Good Automated Manufacturing Practice; Refers to the validation of computerized systems.

GCP

= Good Clinical Practice; valid for clinical trials: Quality requirements for planning and conducting clinical trials.

GDP

= Good Distribution Practice: Controlled, safe drug distribution channel, from leaving the manufacturer through to the end consumer.

GEP

= Good Engineering Practice; relevant to engineering: Good and effective planning of plants.

GLP

= Good Laboratory Practice; relevant to laboratories: Validation of non-clinical safety tests and procedures.

GMP

= Good Manufacturing Practice; Good manufacturing practice for medicinal products: Sum total of national and



international rules relating to medicinal product manufacture and quality assurance, which are intended to protect public health and to protect consumers from dubious products.

GMP-compliant plant design

Plant planning and construction, which is based on the GMP regulations and aims to optimize subsequent GMP-compliant operation, for example easily accessible and cleanable machine components (cf. “Hygiene design” on page 47).

GSP

= Good Storage Practice; relevant to storage: Storage under controlled, constant conditions (temperature, humidity, light).

GxP

= Good x Practice; umbrella term for specific GMP-regulated sub-areas, e.g.: GAMP, GCP, GEP, GLP, GDP, GSP.



HACCP

= Hazard Analysis of Critical Control Points. A critical control point is a step or phase at which a hazard is recognised and eliminated or reduced to an acceptable level through targeted and controlled measures. HACCP is a preventive risk analysis procedure that is primarily used in the food industry and can be seen as a kind of GMP precursor.

Hand disinfection

As germs are spread permanently and through every touch and microorganisms are passed on, the number of germs can only be reduced by periodic hand disinfection. For this reason, hands/gloves must be disinfected before every activity in cleanrooms or hygiene zones or before resuming work. During hand disinfection, a reduction in the bacterial count of 5 log levels (99.999%) is achieved.

HAZOP

= Hazard and operability studies: Method for systematic identification of possible errors by brainstorming using relevant keywords (e.g. none, more, except) applied to relevant parameters (e.g. contamination, temperature). This is used to identify potential risks and hazards.

Head of production

The Head of Production is responsible for ensuring that production is implemented properly, that the production process is validated and that the production personnel are trained (§ 12 AMWHV). The Head of Production must have a sufficient professional qualification. Appropriate proof

of qualification and reliability (certificate of good conduct) must be submitted to the supervisory authority. The Head of Production must always be independent of the Head of Quality Control.

Head of quality control

The Head of Quality Control's responsibilities include the testing of starting materials, intermediate and final products, the approval of specifications, the validation of test procedures and the training of personnel in his division. Statutory requirements with respect to the Head of Quality Control are the reliability required to carry out his tasks and activities, as well as familiarity with the products and procedures.

HEPA filters

= High Efficiency Particulate Air Filter: HEPA filters are particulate filters with an extremely high retention efficiency. Specifications for the classification and testing of HEPA filters can be found in the standards DIN EN 1822-1, DIN EN ISO 14644-3 and DIN EN ISO 29463.

Hygiene design

Hygiene design refers to the hygiene-optimised construction and planning of components, rooms and production facilities. The objectives of hygiene design are, for example, the avoidance of dead spaces, free access to all surfaces for the purpose of cleaning and disinfection and the minimisation of the machine surface (avoidance of deposit areas).

Hygiene zone concept

Activity-specific arrangement of rooms of different air cleanliness classes/clean room classes. Example: Aseptic preparations; aseptic preparation and filling take place in a room of air cleanliness Class A. The surrounding area of A corresponds to cleanliness Class B. The preparation of solutions that are sterile-filtered before filling is carried out in cleanliness Class C. In air cleanliness Class D, system components are handled after washing or before autoclaving.

ICH

= International Conference on Harmonization of Technical Registration of Pharmaceuticals for Human Use; the ICH aims to harmonize the criteria for the authorization of a medicinal product in Europe, the USA and Japan. The European Commission, the FDA, and also the Japanese Ministry of Health Labour and Welfare (MHLW) are members.



Information officer

The legal requirements with respect to the Information Officer are comparable to those imposed on a Qualified Person (see “Qualified Person (QP)” on page 70). The Information Officer is responsible for releasing scientific information about the medicinal product and, in this respect, is responsible for compliance with the principle of not misleading. He must ensure that the labelling, package insert, technical information and advertising are consistent with the content of the authorization and registration. His work therefore forms part of the preventive consumer protection. The Information Officer may, at the same time, hold the position of Qualified Person and Qualified Person for Pharmacovigilance.

In-process controls

Tests carried out during ongoing production are referred to as in-process controls. The aim is to monitor and, where necessary, adapt the process to the given specifications. In a broader sense, inspection of the environment and equipment may also be considered part of the in-process controls.

Installation qualification (IQ)

The installation qualification documents the correct implementation of previously defined requirements with respect to the installation and modification of the plant. The IQ is primarily based on the specifications written in the DQ (see “Design Qualification (DQ)” on page 30). The relevant documents are checked to make sure they are complete and correct, and updated and supplemented where necessary. Furthermore, the IQ documents prove that all equipment components were delivered, assembled and installed professionally and in accordance with the law. Classic IQ tests include monitoring the acceptance procedure, testing the electrical installation and measuring and control points, and testing the inputs and outputs (I/O test).

IPC

See “In-Process Controls” on page 49

IQ

see “Installation Qualification” on page 88

Ishikawa diagram/method

see “Fishbone Diagram/Method” on page 41

ISO 13485

see “DIN EN ISO 13485” on page 31

ISO 14644

see “DIN EN ISO 14644” on page 32

Isolator

Class III safety cabinet; spatially confined, decontaminated element usually with air quality of cleanliness class ISO 5 or higher, which ensures uninterrupted isolation of the interior from the environment (e.g. from personnel). A distinction is made between two types of insulator:

- Closed isolator systems

Sealing throughout the entire work process prevents contamination of the interior from the outside. The material is introduced exclusively via aseptic airlocks.

- Open isolator systems

The system has openings, but these are designed to prevent contamination. This is achieved, for example, by constant overpressure in the interior. Many isolators are operated under negative pressure for the purpose of employee protection.

ISPE

= International Society for Pharmaceutical Engineering; ISPE is an international non-profit organization which currently has 20,000 members in more than 90 countries all over the world, and is engaged in training and sharing information among employees in the pharmaceutical industry. Members are involved in preparing the FDA (see “FDA” on page 39) and EMA (see “EMA/EMEA” on page 36) guidelines and publish various own ISPE Guides. These ISPE Guides are extremely detailed and are state-of-the-art for the pharmaceutical industry.



Japanese Pharmacopoeia (JP)

The Japanese Pharmacopoeia, compiled by the Pharmaceuticals and Medical Devices Agency (PMDA), a sub-organisation of the Japanese Ministry of Health Labour and Welfare (MHLW), comprises four parts:

- General provisions on raw materials and preparations
- General tests and examinations
- Monographs
- General information

A completely revised version of the JP is published every five years.

JP

see “Japanese Pharmacopoeia (JP)” on page 52

LAF/LF

see “Laminar (air) flows” on page 53

Laminar (air) flows

Laminar airflows are enclosures with terminal HEPA filters to protect machines or work areas; usually realised with FFUs (fan filter units). A low-turbulence displacement flow (laminar flow) prevails. The air flow moves exclusively in one direction and in parallel planes at a constant speed. According to Annex 1 (EU GMP guidelines), a guideline value of 0.36-0.54 m/s must be achieved here, provided that aseptic production is involved. Otherwise, different speeds designed for the process are also possible (e.g. in weighing cabins).

Life-cycle model

see “Life-cycle approach” on page 53

Life-cycle approach

Quality assurance approach, to ensure that all QA measures (risk management, qualification, validation, etc.) depict the complete life cycle of a plant or process. The entire concept must be designed for the life-cycle of a process or the product.

LIMS

= Laboratory information and management system; IT system for managing and processing data obtained in the laboratory.

Logbook

A logbook is used for continuous documentation of critical items of equipment. These generally include machinery, plants and devices, and in particular ventilation systems, water systems and rooms. The logbook records all validations, calibrations, maintenance work and repairs, cleaning and sterilization as well as all modifications, conversion work and, where necessary, further operations.

**Low-turbulence displacement flow
(laminar flow)**

Spatially and temporally directed flow profiles are referred to as laminar flow. They are mainly used in pharmaceutical sterile rooms (filling) (cleanroom class A).

Major change

Major changes refer to changes to the process/to a plant that require monitoring, and which influence the product quality and/or process safety. Examples of this are changes in manufacturing/production, a move in the sense of a change of location or changes in the composition/process parameters.

In the case of major changes, a new validation must be carried out.

Manufacturing authorisation

Anyone manufacturing

1. medicinal products within the meaning of Section 2 (1) or (2) no. 1,
2. test sera or test antigens,
3. active substances which are of human, animal or microbial origin or which are produced by genetic engineering, or
4. other substances of human origin intended for the manufacture of medicinal products

requires a manufacturing authorisation according to AMG § 13. This is issued by the competent state authority. In the case of genetically engineered medicinal products as well as active substances and other substances intended for the manufacture of medicinal products which are of human, animal or microbial origin or which are produced by genetic engineering, etc., the decision on authorisation shall be taken in consultation with the competent higher federal authority. The holder of a manufacturing authorisation must ensure that manufacturing and testing are carried out in accordance with the current state of science and technology in accordance with Section 14 para. 1 no. 6a AMG. To this end, he must



operate a GMP-compliant quality management system.

Material flow

Material flow is the coordinated sequence of individual production and storage steps, from the raw materials through to the finished product. The purpose of the Material Flow is to eliminate the inadvertent omission of a quality-defining manufacturing or control step. Moreover, this prevents mix-ups and ensures compatibility with other manufacturing processes.

Matrixing

Matrixing is a cleaning validation method with the objective of reducing the scope of validation overall. The approach is equipment-based implementation.

Media fill test

The media fill test is a method for validating the aseptic execution of filling processes. In this process simulation, filling is carried out with culture media to test whether it is aseptic/sterile. Media fill is often carried out under worst-case conditions.

Medical device term (according to MPG)

in accordance with the Medical Devices Act § 3:

Medical devices are [...] instruments, apparatus, devices, software, substances and preparations from substances or other objects [...] which are intended by the manufacturer to be used for human beings by means of their functions for the purpose of

- a. the detection, prevention, monitoring, treatment or alleviation of diseases,
 - b. recognising, monitoring, treating, alleviating or compensating for injuries or disabilities,
 - c. the examination, replacement or modification of the anatomical structure or a physiological process
or
 - d. the regulation of conception
- and whose main intended effect in or on the human body is achieved neither by pharmacological or immunological agents nor by metabolism, but whose mode of action can be supported by such agents.
-

Method validation (analytical)


Proof that an analytical method, as specified in the test instructions, provides correct and reliable results. The text and methodology are harmonized in the ICH Q2 for the EU, Japan and the USA.

Metrological traceability

The property of a measurement result or of the value of a standard, whereby the result can be related to appropriate stated references, usually international or national standards, through an unbroken chain of comparisons, which all have stated measurement uncertainties; metrological traceability is thus ensured by relating measurement results to international or national standards via an unbroken chain of calibrations.



*Calibration hierarchy
Germany*



Microbiological monitoring

Examination of the (cleanroom) contamination sources air, media, surfaces and personnel for microbial contamination e.g. CFU/m³ or CFU/25 cm².

Minor change

Minor change refers to a change that requires monitoring, and which has an influence on a unit that requires monitoring. This includes, for example, replacing a component, changing a detergent or changing the laundry for work clothes. In the case of a minor change, no new validation is required.

Monitoring

Monitoring compliance with specified parameters, e.g. monitoring the air cleanliness or monitoring the room climate in cleanrooms.

MPG

= Medical Devices Act (Germany); The MPG regulates the circulation of medical devices and thereby ensures the safety, suitability and performance of medical devices as well as the health and necessary protection of patients, users and third parties. The MPG does not apply to medicinal products.



NOAEL

= no observed adverse effect level: Maximum dose of a substance with no negative observable effect.

NOEL

= no observed effect level: Maximum dose of a substance with no observable effect or critical effect.

Official calibration

Official calibration is the official check for compliance with the calibration failure limits. An Official Calibration is carried out exclusively by the Landeseichamt. Only those measuring instruments and material measures with a type approval can be officially calibrated. In contrast to Calibration, during Official Calibration no deviation from the test specimen to a reference is determined. Instruments used to protect consumers and to protect the legal status (e.g. water meters, counter scales, traffic radar gauges) are primarily subject to Official Calibration.

Operational qualification (OQ)


= Operational qualification: Documented evidence that facilities, plants and equipment, as installed or modified, are functioning within the framework of all the intended operating areas as prescribed. The OQ documents that all plants, including all related pieces of equipment, can be operated in line with the specifications. Furthermore, the control of the operating parameters must conform to the previously determined definitions.

Out of specification (OOS)

A result that does not meet the specification.

Out of trend (OOT)

A result which is still within the specifications, but owing to the fact that it does not correspond to the observed trend over an extended period, exhibits a certain abnormality.



Parenterals

Parenteral means “bypassing the digestive tract”. Accordingly, the European Pharmacopoeia defines Parenterals as “sterile preparations which are intended for injection, infusion or implantation into a human or animal body”. The enteral resorption and the the non-specific immune system (saliva, gastrointestinal tract) are bypassed. Therefore, impurities in parenterals are associated with high health risks.

Particle monitoring

Particle monitoring is used to monitor particulate air cleanliness. Excessive particle loading can result in excessive contamination of the relevant product with particles, but also with microbiological organisms.

PEI

= Paul Ehrlich Institute: Federal Institute for Vaccines and Biomedical Drugs and is part of the Federal Ministry of Health (Germany). It is responsible for the approval of clinical trials and for the authorisation of certain groups of medicinal products (biomedical medicinal products: vaccines for humans and animals, antibody-containing drugs, allergens for therapy and diagnostics, blood and blood products).

Performance qualification (PQ)

Proof of the long-term specification conformity of a plant during operation. Here, the interplay or compilation of all plant components is checked and the performance limits are tested. As a result, differentiation between Performance

Qualification and Process Validation is not always clear. The Performance Qualification can be differentiated to the extent that product-specific proof of the effectiveness and reproducibility of the device/plant is to be provided.

Person responsible for technical matters

The person responsible in Switzerland for the direct supervision of the company, who ensures that the guidelines of good manufacturing practice (GMP) are adhered to and who decides on the market release or non-release of a batch. The term “qualified person” is used synonymously in the EU (see “Qualified Person (QP)” on page 70).

Personnel flow

A well thought-out, coordinated flow of personnel is a prerequisite for GMP-compliant production. It forms part of the implementation of the hygienic zone concept and prevents cross-contamination. It is also used for product and personnel protection. The term “Personnel Flow” encompasses requirements to allow access to pharmaceutical areas only via airlocks and changing areas, to only employ appropriately trained personnel, and to constantly determine the number of people required for operating, monitoring and maintaining the facilities.

Ph. Eur.

See “EP” on page 37



Pharmaceutical excipient

Pharmaceutical Excipients are substances which form part of a medicinal product, but are not active ingredients themselves. They are added in order to influence the form of the medicinal product or its release in the organism.

Pharmacology

Pharmacology is the study of the interactions between drugs and living organisms.



PIC/S

= Pharmaceutical Inspection Convention and Pharmaceutical Inspection Co-operation Scheme; merger consisting of many member states from all over the world, which has set itself the goal of working together to further develop GMP and to harmonise the resulting regulations. In addition, in order to prevent multiple inspections, the mutual recognition of inspections is to be improved and the movement of medicines simplified by dismantling trade barriers. The PIC/S issues PIC/S Guides and PIC/S Recommendations.

Postal audit

A postal audit is carried out without an actual visit to the company being audited. Instead, a comprehensive questionnaire is sent by the auditor to the supplier, who independently fills this in with the appropriate information and relevant references. This information may be verified at a later date during an on-site appointment.

PPQ

see “Process performance qualification (PPQ)” on page 66

PQ

see “Performance qualification (PQ)” on page 62

PQR

see “Product quality review (PQR)” on page 67

Pressure cascade

The pressure difference between different rooms and work areas is referred to as a pressure cascade. In cleanroom areas, for example, there is an overpressure compared to the environment with lower air purity in order to direct the overflow in a specific direction and minimise the penetration of impurities (= cleanroom principle). In contrast, there are also work areas in the pharmaceutical industry, such as when handling cytostatics or viruses, where negative pressure prevails in relation to their surroundings (= clean corridor principle). This is to prevent the hazardous substances from escaping.

Primary packaging

The primary packaging is the part of a package that immediately surrounds the product, i.e. is in direct contact with it. Thus, primary packages are often made of aluminium, glass or plastic, since these materials are inert or hardly cause any abrasion.



Primary packaging of medicinal products

Process

Any defined organizational sequence or step in a process chain related to the procurement, handling, manufacture and distribution of medicinal products. Processes are clearly defined and clearly differentiated with regard to responsibilities.

Process capability

Process capability means that a process is manageable, stable and conforms to the specifications. This is the case if the critical parameters are only subject to purely random variation (normal distribution) and the corresponding values are within the upper and lower control limits/tolerance limits.

Process capability study

Statistical method for comparing the process information with the permissible tolerances, to draw conclusions about the process capability.

Process performance qualification (PPQ)

The PPQ is part of the new life-cycle approach, and replaces or includes DQ, IQ, OQ and PQ for the existing validation approach. The stability of the process must be demonstrated in the PPQ.
(cf. “Life-cycle approach” on page 53).

Process validation (PV)

Process validation is documented evidence that the process, within certain parameters, produces a medicinal product that fulfils predefined specifications and quality

attributes, in a manner that is effective and reproducible. Here, it must be demonstrated that even difficult-to-control critical process steps follow a predefined sequence and the overall process is completely reproducible - with consistent quality and in compliance with the specifications. The scope of the PV is determined by risk management.

Product quality inspection

See “Product quality review (PQR)” on page 67

Product quality review (PQR)

= Periodic product quality review; regular quality reviews of medicinal products, with the aim of confirming the consistency of the current process and the adequacy of the current specifications for both the starting materials and for the finished product, in order to highlight trends and identify product and process improvements. The PQR should be carried out annually, taking into account previous review results.

Product specification

A product specification should include all the information necessary for preparing the precise written instructions for processing, packaging, quality control, batch release and shipment of a product.

Prospective qualification

Qualification of a new plant before the start of production.



Prospective validation

Validation before the start of production/marketing of a pharmaceutical product.

PV (process validation)

see “Process validation (PV)” on page 66

Pyrogenicity/pyrogens

Pyrogens are substances that can cause fever when administered parenterally. These can be molecular compounds such as lipopolysaccharides (bacterial endotoxins; decay product of a bacterium) or particles, e.g. abrasion from injection bottles and microscopic plastic particles.

QA

see “Quality assurance (QA)” on page 71

QbD

see “Quality by design (QbD)” on page 72

QP

see “Qualified person (QP)” on page 70

Qualification

Qualification is documented proof that a device/plant is suitable for the intended purpose, to fulfil the specified functions or to produce products, and that these meet the regulations and standards on a permanent basis (= are GMP-compliant, see “GMP” on page 44)

Qualification master plan

The Qualification master plan is a superior document which depicts the qualification strategy and organizational structure in general. The individual qualification objects are defined and the necessary qualification steps are described, with the type and scope of qualification activities. It therefore serves as an overview of equipment and plants with regard to scheduling, and defines the appropriate responsibilities for completing the qualification activities.

Qualification plan

The qualification plan contains the goal, subject and scope of the qualification, the designation of persons and responsibilities within the qualification team and the



description of the qualification strategy. Key components are the detailed designation of individual tests, the descriptions relating to their implementation, and the corresponding acceptance criteria (also referred to as test plans, which may also be separate from the qualification plan). Furthermore, the plan should describe the qualification object and, if necessary, the process, should indicate the critical plant parameters and include a list of documents. The document must finally be released.

Qualification report

The qualification report always represents the conclusion of a qualification. All results are summarized here. Changes to the test plans and any deviations must be documented accordingly. It should be noted that at this point, all critical deviations must be remedied, only non-critical deviations can be accepted with appropriate justification. The report must also include the maintenance programs, recalibration data, operating instructions, SOPs and the qualification status of the installation. The qualification report is a prerequisite for clearance to use the plant or for validation.

Qualified person (QP)

The qualified person must have proof of the necessary expertise (authorized pharmacist or medical/scientific degree with additional qualification) according to § 15 AMG (Germany). Additional requirements are the reliability required to carry out the tasks and activities as well as sufficient familiarity with the products and procedures (§ 16 AMWHV). The qualified person is responsible for compliance with the relevant regulations governing the manufacture, testing and release of medicinal products prior to placing

a drug on the market (§ 19 AMG). Their tasks therefore include:

- The batch release for placing on the market
 - Securing reserve samples
 - Checking whether a company's QM system is being adhered to
 - Being responsible for complete documentation, in order to demonstrate compliance with all regulations.
-

Qualified person for pharmacovigilance

The tasks of the qualified person for pharmacovigilance include:

- Collecting reports on drug risks, assessing them and coordinating necessary actions
- Monitoring clinical trials with regard to drug risks
- Identifying serious side effects, interactions or misuse
- Notifying supervisory authorities in the event of an abnormal restriction of supply (stopping deliveries, recall).

The qualified person for pharmacovigilance must have appropriate expertise in the form of a completed university degree plus at least two years of professional experience.

In principle, he should work independently of sales and distribution units; however, it is possible for him to act as a qualified person at the same time (§ 63a AMG).

Quality assurance (QA)

Quality assurance is a far-reaching concept which covers all the areas that individually or collectively control the quality of a product. It constitutes all the planned measures, undertaken to ensure that medicinal products are of the quality that is required for their intended use.



Quality by design (QbD)

Quality by design is a holistic, risk-based approach to the development and manufacture of medicinal products, which aims to develop a process that identifies critical, quality-relevant steps, measures their impact, and determines this within a specified “design space”.

Quality management manual

The quality management manual is a superior, binding document which depicts a company's quality policy and guidelines. As an essential element for long-term implementation of the quality management system, it includes a description of the operational and organizational structure and refers to the relevant procedures, standards and regulations.

Quality risk management (QRM)

(Quality) risk management is a systematic process for the assessment, control, communication and monitoring of risks to the quality of medicinal products over the entire life-cycle of the product. According to ICH Q9, the assessment of quality risks should be based on scientific knowledge and should always be viewed in the context of patient protection. This requires extensive knowledge of the process as well as clearly defined framework conditions. quality risk management includes risk assessment, risk control, risk monitoring and risk communication. (see “Risk assessment” on page 76, “Risk monitoring” on page 77, “Risk communication” on page 76, “Risk control” on page 76).

RABS

see “Restricted access barrier system (RABS)” on page 75

Recovery test

Measurement of the time required by a turbulent cleanroom to reduce a given particle concentration/contamination by a certain factor. In the 1:100 recovery test in cleanrooms, the recovery time (time span) required to reduce the initial concentration of particles to 1 % is determined.

Remedies

Common term for medicinal products and medical devices in Switzerland (TPA; Art. 2a).

Reproducibility

Reproducibility is understood to be consistent product quality and invariable production processes. A process is GMP-compliant only if its result is reproducible. This is the only way to ensure that, for example, when testing a batch by random sampling, the findings obtained from this can also be transferred to all the individual products in this batch.

Requalification

Qualification following changes or periodic, cyclical inspection of critical parameters to ensure that the plant/device is still in a qualified state.



Requirement specification

Forming part of the qualification, the requirement specification documents the requirements of the client regarding the scope of delivery and services. These technical or regulatory requirements are defined by the relevant departments (Engineering and QA) in collaboration with the operator.

Contents of the requirement specification may be:

- Purpose of the device/plant
 - Key technical data such as sizing
 - Details of the design (materials, surfaces in contact with the product)
 - The nature of the control system
 - Warranty services/service requirements for the suppliers
 - Requirements with respect to materials and surfaces
 - Information about customer service (availability, response time, etc.)
 - Requirements for GMP compliance
-

Reserve sample

A reserve sample is a sample, for example from a fully packaged unit from a finished product batch, which is stored for identification purposes.

Responsibility delimitation agreement

This completely and unambiguously sets out the interfaces, tasks and responsibilities between those involved in the manufacture, handling and distribution of a medicinal product. It provides the basis for legally secure cooperation, which, for example, ensures that all requirements for ensuring the quality of a medicinal product are fulfilled.

Restricted access barrier system (RABS)

RABS is a concept for isolating a machine, often used in aseptic production or as personal protection in the case of highly active substances. As a mixture of conventional cleanroom technology and isolator technology, active intervention is only possible using gloves; the process itself remains separated from the operator.



RABS
(Image: Franz Ziel GmbH)

Retrospective qualification

A retrospective qualification is a qualification for already established systems or a qualification based on historical data. Retrospective qualification can only be carried out if sufficient data is available for subsequent assessment and review of the critical parameters. From a GMP perspective, a retrospective qualification is no longer accepted.

Returns

The return of a medicinal product to the manufacturer or distributor, regardless of whether or not there is a quality defect.

Revalidation

A periodic, cyclical inspection or repetition of a validation to ensure that changes to the process or equipment made in accordance with certain change control procedures do not impair the process characteristics or the product quality.

Risk analysis (RA)

The risk analysis forms part of the risk assessment. In the risk analysis, the assessment or weighting of the risk/possible failure previously identified during the risk assessment is carried out. In GMP-regulated areas, the risk analysis is often carried out using the FMEA method (see “FMEA (Failure Mode and Effects Analysis)” on page 42).

Risk assessment

The goal of the risk assessment is to identify hazards, as well as to analyze and assess the risks arising from these hazards. To this end, the problems and issues posed by the risk must first be clearly defined as part of the risk assessment. Firstly, potential hazards are identified (risk identification), as a result of which the risk analysis takes place (what is the probability of occurrence and of detecting the fault?). Finally, the risk assessment (what are the consequences?/what is the extent of this?) is carried out.

Risk communication

The findings obtained from the risk analysis process should be communicated throughout the quality risk management process; however, all decision-makers and participants really need to be informed about the conclusions, because identifying a risk can only contribute to the quality assurance if all process participants are informed about it and it can be purposefully avoided.

Risk control

The goal of risk control is to reduce risks to an acceptable level. Appropriate measures are established to reduce a risk

(risk reduction) or an acceptable risk is classified as non-critical (risk acceptance). (see “Risk reduction” on page 77).

Risk management

see “Quality risk management (QRM)” on page 72

Risk monitoring

Since the risk assessments made as part of the quality risk management only ever represent a snapshot, they must be checked at regular intervals. This ensures the timeliness and suitability of the risk assessment throughout an entire life-cycle, and takes account of changes or new sources of failure and integrates these into the risk management.

Risk priority number (RPN)

The formula for determining the risk priority number (RPN)

is: $RPN = A \times B \text{ (or } S) \times E$

The individual parameters are defined as follows:

P = Probability of occurrence

S = Severity of the failure

D = Detection probability

Risk reduction

Risk reduction forms an integral part of risk control, and includes measures to reduce the extent and probability of a failure, or to improve or increase the detectability of a failure. The risk assessment should be re-evaluated once the appropriate measures have been implemented and the potential change assessed.

Risk-based qualification systems

The goal of the risk-based qualification system is to ensure GMP compliance throughout the entire life-cycle of a plant/device. To this end, the risk analysis, i.e. determining the influencing factors which have a negative impact on product quality, is used as the basis for the qualification measures and for determining their scope. The effort put into the qualification and documentation of it are tailored to the seriousness and significance of the risks.

Robustness

Robustness describes the capacity of a system/process not to respond to external changes.



Sanitisation

Sanitisation is used for water systems. In hot sanitisation, hot water or steam (80-85 °C) is used to reduce the bacterial count as far as possible or completely. In cold sanitisation, sanitisation is carried out with ozone or, for example, caustic soda.

Secondary contamination

Secondary contamination refers to contamination of the product after manufacture, e.g. due to improper sampling, packaging or storage.

Secondary packaging

The secondary packaging encloses the primary packaging and, unlike this, is not in direct contact with the product.

Self-inspection


Self-inspection is a critical evaluation and review of in-house processes. The Head of Production and the Head of Quality Control play a fundamental role in carrying this out. This internal quality audit is mandatory in the AMWHV and the EU GMP Guidelines.

Shell model

The shell model states that an overpressure of 10-15 Pa should be maintained in a cleanroom compared to neighbouring areas with lower air purity. In addition, the personnel flow should be organised in such a way that the passage through different zones is delayed. Doors and airlocks should therefore not be positioned directly behind



each other in a row, but offset in order to prevent rapid passage through the various cleanroom zones.



Sinner's circle

Sinner's circle

Sinner's circle describes the four parameters that influence a cleaning process. The representation in a pie chart illustrates the combinability of the various influencing factors. The success of a cleaning process is just as dependent on the appropriate chemical and mechanical action as it is on the duration of the action and the prevailing temperature. An ideal combination of these factors is a prerequisite for a GMP-compliant and economical cleaning process.

SIP

= Sterilisation in place = sterilisation in a closed system:
SIP is a fully automatic sterilisation process using superheated steam or a chemical process, i.e. all surfaces of a system that come into contact with the product can be sterilised without major disassembly. One example of the use of SIP is in pharmaceutical production plants (often in combination with CIP).

Site acceptance test (SAT)

SAT refers to the acceptance of a device/plant after delivery. All the requirements specified in the requirement specification and the functional specification are checked as part of this process. The site acceptance test is used to determine the as-built state. Subsequent changes must therefore be taken into consideration in the manufacturer's technical documentation.

Site master file (SMF)

= Company description; The site master file (SMF) is an internally-generated company description for external authorities and customers. This should include general information about the company, the QM system, products, self-inspection and relevant plants. Requirements for the SMF are explained in the GMP Guidelines Part III.

SOP (standard operating procedure)

SOPs are documents that provide organizational, administrative, and technical information and instructions for carrying out regularly recurring work processes. They are aimed primarily at a company's employees and are intended to ensure that quality-relevant work is carried out correctly by every employee right from the start.

Specification

The specification covers the entire scope of testing, including the test instructions, which are established for each specific product and which are, in principle, based on the latest developments in science and technology (e.g. pharmacopoeial monograph, guideline on drug testing). This includes the establishment of acceptance criteria as well as specific requirements for storage.

Sterile filtration

When bacteria are removed using sterile filtration, the microorganisms are separated by the filtration, as only small molecules can pass through the membrane. It is the most important process in the pharmaceutical, cosmetics and food industries. Sterile filtration is often used for heat-



sensitive solutions, such as serum-containing tissue culture solutions.

Sterility

Sterility refers to the complete absence of living micro-organisms, including their resting stages (such as spores).

Sterilization

During sterilization, all micro-organisms are killed or viruses inactivated during reproduction and dormancy. Sterilization in GMP areas is carried out physically by means of thermal processes (heat treatment) or chemical processes (e.g. via ethylene oxide). Sterilization via high-energy radiation is also frequently used (e.g. gamma radiation).

Stress test

A stress test is used to check the stability of a product or process under extreme conditions (high temperatures, humidity, etc.). In the case of medicinal products, this includes the light stability test, for example.

Supplier audit

Auditing of a company/organization (supplier) by a customer (see.“Audit” on page 14).



Swissmedic

Swissmedic is the Swiss authorisation and control authority for therapeutic products. Swissmedic's activities are based on therapeutic products legislation. As a federal institution under public law based in Bern, the Swiss Agency for Therapeutic Products Swissmedic is independent in its organisation and management. The diverse activities are based on the legal mandate. The core competences of Swissmedic include

- Authorisation of medicinal products
 - Operating licences for production and wholesale as well as inspections
 - Market surveillance of medicinal products and medical devices
 - Clinical studies and the laboratory analysis of drug quality
 - National and international cooperation
-



TAMC (Total Aerobic Microbial Count)

= total number of aerobic microorganisms

Test plan

A test plan is a document that describes the objective(s), design, methodology, statistical considerations as well as the organization of a test prospectively.

Therapeutic products act (HMG)

Federal Act on Medicinal Products and Medical Devices (Switzerland)

Third-party audits

Audit by a third party not directly involved in the manufacture of a product (not manufacturer or supplier). For example, according to GMP regulations, a pharmaceutical manufacturer is required to audit its active ingredient suppliers to ensure that the active ingredients were produced in accordance with Good Manufacturing Practice. However, the pharmaceutical manufacturer can also use an appropriately qualified, impartial third party to have these mandatory audits carried out at the supplier.

TOC measurement

= Total Organic Carbon measurement; the TOC value indicates the sum of the total organic carbon, which is contained in a water sample, for example. The measurement is based on the determination of the amount of CO₂ released by the oxidation of the carbon compounds contained in the water. A TOC measurement is often carried

out in conjunction with a cleaning validation in order to determine the water quality.

Traceability

Traceability refers to the ability to trace all the steps and processes of a product, a batch or even a measure itself at a later date.

Traceability matrix

The traceability matrix is used to display the relationships between user requirements, technical requirements, specifications and test cases. It provides proof that the user requirements, via the technical requirements, have been fully converted into technical specifications, which the project manager is obligated to adhere to. It is also possible to link the requirement specification and risk analysis requirements with the qualification tests.

Track & trace

Track & trace refers to the individual labelling of each product, as well as the recording of every movement and every transportation step that a product goes through, from manufacture to end consumer. In the pharmaceutical industry, this method can be used to combat product counterfeiting, because the sale of each pharmaceutical product can be retraced in order to determine where the product comes from and whether it is an original or a copy.

Turbulent flows

Turbulent flows are defined as temporally and spatially non-directional flow profiles. They are used in most pharmaceutical cleanrooms (class B-D) as they are very suitable for removing particulate impurities and heat loads. Turbulent flows are generated with the help of ceiling swirl diffusers, for example.

TYMC (Total Yeasts/Moulds Count)

= Total number of yeasts and moulds

URS (user requirement specification)

In the URS, the requirements for the device/plant being manufactured with respect to the product to be produced are described from the user's perspective.

The URS, together with the technical and regulatory GMP requirements for the plant, forms the requirement specification.

USP


= United States Pharmacopeia; Pharmacopoeia of the USA.

The collection of official standards that apply to medical devices and pharmaceutical substances within the USA; published by the United States Pharmacopeial Convention (usually also called USP).



V model

In the so-called V Model, all activities and documents containing a qualification and validation are depicted in their logical sequence. Moreover, the direct links between the requirement documents “URS (user requirement specification)” on page 87, “functional specification” on page 43, “requirement specification” on page 74) and the corresponding qualification documentation (“process performance qualification (PPQ)” on page 66, “operational qualification (OQ)” on page 61, “IQ” on page 50) are demonstrated.



VAC system

= Ventilation/air conditioning system; system with mechanical air conveyance to fulfil a ventilation task. VAC systems are further subdivided into systems with or without a ventilation function. Air handling units with a ventilation function work with outside air, while air handling units without a ventilation function work without outside air.

Validation

Provision of documented proof which provides a high degree of assurance that a specific process or a Standard Operating Procedure will produce a product that conforms to the pre-defined specifications and quality characteristics – in accordance with AMWHV § 2-16. The validation therefore provides proof that methods, processes, plants, equipment, materials and systems bring about the expected results in accordance with the principles of Good Manufacturing Practice. Validation therefore ensures and documents the most important attributes of a process: Reproducibility and Robustness.

Validation master plan (VMP)

The validation master plan (VMP) specifies a company's validation strategy and philosophy and summarizes concepts, intentions, responsibilities and procedures with regard to validation. According to EU GMP Guidelines Annex 15, "all validation activities should be planned. The key elements of a validation program should be clearly defined and documented in a validation master plan (VMP) or similar document". The qualification master plan may form part of the VMP.



Validation matrix

A validation matrix is used to depict the relational links between the individual validation components (products, processes, systems) and the assigned actions (validation/qualification tasks). In order to simplify the overview when it comes to complex validations, the appropriate responsibilities and priorities should also be noted.

Validation plan

The validation plan is written before the validation is carried out, and it contains information about the product (specifications, analytical methods) and about the process (process description including flow chart, RA) as well as about rooms and facilities (allocation of rooms, hygienic status, calibration status) and about the process validation (tests, sampling, analytical methods, acceptance criteria, timetable, responsibilities).

Validation report

The validation report is used to document the validation. This contains the production protocol, which includes the results of the in-process controls, the results of the validation tests including any deviations detected, and also the evaluation and assessment of the validation and the related implications with regard to routine production, change control and, where necessary, revalidation.

VDI 2083

VDI 2083 is the guideline of the Association of German Engineers on the subject of cleanroom technology. Sheets 1 to 21 contain the guidelines for various sub-areas, such

as particle purity classes of air, measurement technology in cleanroom air, purity of process media, etc.



Warning letter

A warning letter is issued by the FDA to a pharmaceutical company if critical deficiencies were identified and not remedied during a previous inspection (or audit). The team of inspectors lists the deficiencies on the 483 form. The company is granted a period within which the deficiencies must be dealt with, otherwise there is a risk that the authorization will be rejected or imports banned. A warning letter is published by the FDA on its website, in order to bring the shortcomings therein and the company concerned to the notice of the public.

Warning limit

The warning limit is a defined limit value, which enables early warning of possible deviation from regular operating parameters. This does not necessarily involve corrective measures, but the cause does need to be investigated.



WHO

= World Health Organization; the World Health Organization is the superior authority of the United Nations when it comes to international healthcare. It is currently made up of 194 member states. The WHO agenda contains six key points:

- Two health objectives: Promoting development and promoting health and safety;
 - Two strategic requirements: Strengthening the health system and utilising research results, data and findings;
 - Two operational approaches: Expanding partnerships and improving performance.
-

WIP

= Washing in place; automated cleaning process within a system, which differs from CIP in that WIP usually involves additional manual cleaning steps, such as cleaning individual system parts (see “CIP” on page 22).

Work instruction

see “SOP (Standard Operating Procedure)” on page 81

Worst-case scenario

The worst-case scenario describes the most critical state that could possibly occur. This means, for example, that process parameters reach their upper or lower limit values, making it significantly more likely that process or product failures will occur.





ZLG

= Central Authority of the Länder for Health Protection with regard to Medicinal Products and Medical Devices; as a coordinating body for the German federal states in the field of human and veterinary medicine, ZLG is responsible for maintaining and improving the quality and safety of medicinal products and medical devices. Thanks to standardization of the inspection standards within Germany, which ZLG initiates, in comparison to Europe, Germany is portrayed as one cohesive unit despite federal structures in the healthcare system.

GxP Regulations and Guidelines

Germany:

- Act on the Marketing of Medicinal Products (Medicinal Products Act - AMG)
- Ordinance on the application of good manufacturing practice in the manufacture of medicinal products and active substances and on the application of good professional practice in the manufacture of products of human origin (Ordinance on the Manufacture of Medicinal Products and Active Pharmaceutical Ingredients – AMWHV)
- Aide mémoire 07121105 of the Central Office of the Federal States for Health Protection with regard to Medicinal Products and Medical Devices: Inspection of qualification and validation in pharmaceutical manufacturing and quality control

Europe:

- EC Guidelines on Good Manufacturing Practice (EU GMP Guidelines Part I, II, III; Annexes 1-21), including supplementary guidelines
- Guidelines on Good Distribution Practice for medicinal products for human use (GDP Guideline)

USA:

- 21 CFR 210 Current Good Manufacturing Practice in Manufacturing, Processing, Packing, or Holding of Drugs; General
- 21 CFR 211 Current Good Manufacturing Practice for Finished Pharmaceuticals
- 21 CFR 11 Electronic Records; Electronic Signatures
- FDA Guidance for Industry Process Validation: General Principles and Practices, January 2011
- FDA Guidance for Industry Sterile Drug Products Produced by Aseptic Processing – Current Good Manufacturing Practice

Other/standards:

- DIN EN ISO 14644 Cleanrooms and associated controlled environments
- DIN EN ISO/IEC 17025 Quality management and general requirements for the competence of testing and calibration laboratories

More information/contact

Testo Industrial Services

Further information can be found on our websites:

www.testotis.com

www.testotis.ch

www.testotis.at

We would also be happy to send you information on our services, seminars or other topics in the areas of qualification, validation and calibration.

Our contact details:

Testo industrial services GmbH
Gewerbestraße 3
D-79199 Kirchzarten Germany
GERMANY

Phone: +49 7661 90901-8000
E-mail: info@testotis.de

Testo industrial services GmbH
Carlberggasse 66 / Gate 4
A-1230 Vienna
AUSTRIA

Phone: +43 1 486 26 11 0
E-mail: info@testotis.at

Testo industrial services GmbH
Gewerbestrasse 12a
CH-8132 Egg
SWITZERLAND

Phone: +41 43 277 1030
E-mail: info@testotis.ch

Testo Saveris

You will find more information on our worldwide representatives on our website.

www.testo.solutions

We will be happy to provide you with additional information on our solutions, products or other topics relating to Testo Saveris on request.

Our contact details:

Testo Saveris GmbH

Celsiusstrasse 2

79822 Titisee-Neustadt

GERMANY

Phone: +49 7653 845 3004

E-mail: info@testo.com

